Skip to main content
  1. Right Decisions
  2. Back
  3. Dermatology pathways
  4. Nummular discoid eczema
Announcements and latest updates

Right Decision Service newsletter: March 2024

Welcome to the Right Decision Service (RDS) newsletter for March 2024. Please forward this newsletter to others who may be interested. They can contact olivia.graham@nhs.scot to be added to the circulation list.

Promotion and communication resources

Promotional flyers are now available in the Learning and Support area of RDS:

What is RDS and what impact does it have? (infographic)

General RDS flyer

Being a partner in my care: Realistic medicine app for citizens

Managing medicines for patients and carers app

Home care decisions app

Child protection app (South Lanarkshire HSCP)

All except the infographic are also available as editable Word versions. Please contact his.decisionsupport@nhs.scot  if you would like Word versions.  

Redesign and improvements to RDS

Search and browse improvements are progressing well and the plan is still to release these in mid-May.  The first stages of work on archiving and version control are complete. User stories (requirements) are being defined for:

  • Deep linking to individual toolkit URLs/QR codes
  • Translating content from a structured Word document directly into RDS
  • Capability to review and edit changes made to shared content

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

A big thank you to all of you who have completed our Impact and Value questionnaire. The data from this will be really helpful in informing the first draft of the business case for long term provision of the RDS. This will be reviewed by the National Advisory Board for RDS later this month.

We welcome further responses. If you haven’t yet completed the survey, please follow this link, and please encourage other RDS toolkit leads and users to do so.

New toolkits

A few examples of toolkits published to live in the last month:

 

Toolkits in development

Some of the toolkits the RDS team are currently working on:

  • Updates to the Respiratory prescribing guidance and Manage Medicines for patients and carers toolkits
  • Respiratory Managed Clinical Network Pathways
  • Child abuse pathways in NHS Tayside
  • Patient information leaflet collection in NHS Borders
  • Referral management toolkit for NHS Borders
  • NHS Lothian – Infectious diseases; Acute oncology guidelines; Royal Infirmary of Edinburgh Emergency Care.

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Learning opportunities

The RDS Learning working group is progressing with developing training resources for editors, and intend to have resources to share by end of June. This includes resources for:

  • Each stage of the development journey for RDS toolkits – Scoping to Implementation/Evaluation and Maintenance.
  • RDS content governance.
  • Core functionality – learning bytes.

 

Editor webinars

Just a reminder that we are offering webinars for existing and potential new editors on the following dates:

  • Wednesday 10 April 3.30-4.30 pm
  • Thursday 18 April 12-1 pm

 

To book for one of these webinars, please complete the registration form at https://forms.office.com/e/eGjKqNVjeF

Quality audit

Many thanks to all of you who have met with me recently to complete or clarify your responses to the quality audit survey at the end of last year.  Work to complete the quality audit for all toolkits published on RDS prior to November last year will continue for the next few months.

Implementation projects

The RDS team is now working with Moray HSCP to evaluate impact of the new RDS toolkit “Preventing progress of diabetes”  (https://preventdiabetes.scot.nhs.uk ) to support people at high risk of diabetes type 2 and those who are candidates for remission. We are looking at the impact of use of the app with SMS prompts on people’s readiness for lifestyle change over an 8 week period. This includes comparing impact in people who have a call with a dietitian in addition to using the app to people who only use the app.

If you have any questions about the content of this newsletter, please contact us on his.decisionsupport@nhs.scot.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

 

Nummular discoid eczema

Warning

Nummular eczema/discoid eczema: Cutaneous eruption characterized by coin-shaped plaques of eczema. The plaques usually occur on the extensor surfaces of the extremities, but the face and trunk may also be involved. Plaques are extremely itchy. Each plaque begins as a small group of red spots and tiny bumps (papules) or blisters (vesicles), which cluster together and grow rapidly into a red, swollen, round plaque which often weeps or develops a crusted surface. Plaques may become infected at a later stage. After a while the plaques become dry and scaly. 

The cause is unknown. Prevalence is around 1 in 500 people. There is a peak incidence in both males and females of around 50-65 years of age. It is less commonly seen in children. The condition can respond poorly to treatment compared to other forms of eczema, and typically requires the use of potent topical steroids. 

Treatment/ therapy

Mild: ... Slight but definite erythema (pink), slight but definite induration/papulation, and/or slight but definite lichenification. No oozing or crusting. Disease limited in extent.   

  • Advise patient on the avoidance of irritants (e.g. soap). 
  • Prescribe generous amounts of emollients; advise frequent and liberal use. 
  • Moderate potency topical corticosteroids eg.  betamethasone valerate 0.025% or clobetasone butyrate 0.05% 

Moderate: … Clearly perceptible erythema (dull red), clearly perceptible induration/papulation, and/or clearly perceptible lichenification. Oozing and crusting may be present. Disease fairly widespread in extent. 

  • Advise patient on the avoidance of irritants (e.g. soap). 
  • Prescribe generous amounts of emollients; advise frequent and liberal use. 
  • Potent topical corticosteroids eg. betamethasone valerate 0.1% or mometasone 0.1%. If no improvement, may require the use of clobetasol propionate 0.05% (super potent) daily for up to 2 weeks, then review (trunk and limbs, not face and flexures). 
  • Sedating antihistamine at night if sleep disturbed and non-sedating antihistamine for daytime itch if required. 
  • Treatment of secondary infection: antibiotic as appropriate according to swab result. 

Severe: … Marked erythema (deep or bright red), marked induration/papulation, and/or marked lichenification. Oozing or crusting may be present. Disease is widespread in extent. 

  • Advise patient on the avoidance of irritants (e.g. soap). 
  • Prescribe generous amounts of emollients; advise frequent and liberal use. 
  • Refer to dermatologist. Commence treatment in primary care whilst waiting for appointment. 
  • Super potent topical corticosteroids eg. clobetasol propionate 0.05% daily for up to 2 weeks, then review (trunk and limbs, not face and flexures). 
  • Sedating antihistamine at night if sleep disturbed and non-sedating antihistamine for daytime itch if required.. 
  • Treatment of secondary infection: antibiotic as appropriate according to swab result. 
  • Other treatments may be required, such as phototherapy or oral immunosuppressant drugs. 

Referral Management

Mild: ... Slight but definite erythema (pink), slight but definite induration/papulation, and/or slight but definite lichenification. No oozing or crusting. Disease limited in extent.

Manage in primary care; do not refer.  

Seek advice and guidance where there is diagnostic uncertainty. 

Moderate: … Clearly perceptible erythema (dull red), clearly perceptible induration/papulation, and/or clearly perceptible lichenification. Oozing and crusting may be present. Disease fairly widespread in extent. 

Manage in primary care.  

Refer to secondary care service if multiple treatments in primary care have failed. 

 

Severe: … Marked erythema (deep or bright red), marked induration/papulation, and/or marked lichenification. Oozing or crusting may be present. Disease is widespread in extent.

Refer to dermatologist if the patient has not responded to optimum topical therapy (including super potent topical corticosteroids). Could be offered a video consultation. 

Clinical tips

  • Initially, these plaques are often swollen, and ooze fluid. The appearance can be confused with secondary infection. 
  • Antibiotics are rarely indicated for discoid eczema.  
  • Plaques tend to be very itchy, particularly at night. 
  • Over time, the plaques may become dry, crusty, cracked and flaky. The centre of the plaque also sometimes clears, leaving a ring of discoloured skin that can be mistaken for ringworm. Tinea would be suggested by asymmetrical distribution and can be confirmed with skin scrapings for mycology. Tinea corporis is not commonly seen in adults. 
  • Discoid eczema usually requires at least potent topical corticosteroids. 
  • On lighter skin, plaques will be pink or red. On darker skin, plaques can be dark brown or paler than the skin around them. Discolouration can persist for months after the condition has cleared. 
  • Differs from psoriasis in that plaques tend to be a lighter red, the border fades gradually at the periphery and the presence of exudate / crust as opposed to scale. 

ICD search categories

Inflammatory 

ICD11 code - EA82 

Editorial Information

Last reviewed: 23/05/2023

Next review date: 23/05/2025

Author(s): Adapted from the BAD Referral Guidelines.

Version: BAD 1

Co-Author(s): Publisher: Centre for Sustainable Delivery, Scottish Dermatological Society.

Approved By: Scottish Dermatological Society